Ignite Creation Date:
2024-05-06 @ 1:59 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01941680
Status:
COMPLETED
Last Update Posted:
2021-06-03
First Post:
2013-09-03
Brief Title:
High Risk Adult T-cell LeukemiaLymphoma ATLL-HR and Allogeneic Transplant
Sponsor:
University Hospital Center of Martinique
Organization:
University Hospital Center of Martinique
Study Overview
Official Title:
Observational Prospective Study Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon -Polychemotherapy in High Risk Adult-T-cell LymphomaLeukaemia T-cell LymphomaLeukaemia Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATLL-HR-01
Brief Summary:
Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana They all receive Zidovudine and Pegylated Interferon ZPI For patients younger than 65 years old an allogeneic donor is searching out Patients included at relapse and with lymphoma clinico-biological subtype also receive chemotherapy CT Responses are assessed during ZPI-CT and eligible patients depending on age comorbidities and response criteria receive allogeneic transplant Patient follow-up is planned for 3 years old
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-A00327-38 | OTHER | AFSSAPS | None |